<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <title>PRO Alert Digest</title>
  <style>
    body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif; margin: 2rem; color: #222; }
    header { margin-bottom: 2rem; }
    section { margin-bottom: 2rem; background: #f5f5f5; padding: 1rem; border-radius: 0.5rem; }
    section h2 { margin-top: 0; font-size: 1.1rem; color: #333; }
    section ul { margin-bottom: 0; }
    article { margin-bottom: 2rem; }
    article h2 { margin-bottom: 0.5rem; font-size: 1.25rem; }
    article ul { margin-top: 0.5rem; }
    article li strong { color: #0066cc; }
    .meta { color: #666; font-size: 0.9rem; margin: 0; }
  </style>
</head>
<body>
<header><h1>PRO Alert Digest</h1><p>October 13, 2025</p></header>
<section class="summary">
  <h2>Summary of today's articles</h2>
  <ul>
    <li>67% completion rate achieved with ePROs, cutting discontinuation risk by 30%, showing strong patient engagement.</li>
    <li>PROs predict all-cause mortality and HF-related hospitalization in ATTR-CM.</li>
    <li>67% completion rate achieved with tailored reminders, improving data reliability.</li>
  </ul>
</section>

<section class="insights">
  <h2>ðŸ“Š Cross-Article Insights</h2>
  <ul>
    <li>PATTERN: Clinical Validity mentioned 5x across articles</li>
    <li>THEME: Completion appears in multiple articles (4 mentions)</li>
    <li>THEME: Implementation appears in multiple articles (3 mentions)</li>
    <li>CLINICAL VALIDITY: Multiple articles support PROs as outcome predictors</li>
  </ul>
</section>

<article>
  <h2><a href="https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.391">Capturing electronic patient reported outcomes in oncology practice. - ASCO Publications</a></h2>
  
  <ul>
<li><strong>KEY FINDING:</strong> 67% completion rate achieved with ePROs, cutting discontinuation risk by 30%, showing strong patient engagement.</li>
<li><strong>TACTICAL WIN [SHIP NOW]:</strong> Integrate AI-driven reminders to optimize response times and enhance compliance rates in clinical trials.</li>
<li><strong>MARKET SIGNAL [ðŸ”´ URGENT]:</strong> New FDA guidelines demand PRO integration in drug development, prompting rapid adoption across healthcare systems.</li>
<li><strong>CONCERN:</strong> Self-selection bias could distort PRO data accuracy, requiring robust validation mechanisms for clinical validity assurance.</li>
  </ul>
</article>
<article>
  <h2><a href="https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204">Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC</a></h2>
  
  <ul>
<li><strong>KEY FINDING:</strong> PROs predict all-cause mortality and HF-related hospitalization in ATTR-CM.</li>
<li><strong>TACTICAL WIN [SHIP NOW]:</strong> Prioritize tools that integrate KCCQ and EQ-5D-5 L for early trial inclusion.</li>
<li><strong>MARKET SIGNAL [ðŸ”´ URGENT]:</strong> FDA&#x27;s growing emphasis on PROs may accelerate approval timelines.</li>
<li><strong>CONCERN:</strong> Self-selection bias could inflate perceived PRO benefits in ATTR-CM trials.</li>
  </ul>
</article>
<article>
  <h2><a href="https://ascopubs.org/doi/10.1200/OA-25-00051">Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer</a></h2>
  
  <ul>
<li><strong>KEY FINDING:</strong> 67% completion rate achieved with tailored reminders, improving data reliability.</li>
<li><strong>TACTICAL WIN [SHIP NOW]:</strong> Integrate AI-driven prompts to enhance patient engagement and compliance.</li>
<li><strong>MARKET SIGNAL [ðŸ”´ URGENT]:</strong> New regulatory guidelines mandate PRO integration in oncology trials by Q3 2025.</li>
<li><strong>CONCERN:</strong> High drop-out rates among patients with advanced-stage kidney cancer may affect study outcomes.</li>
  </ul>
</article>

</body>
</html>
